Efficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients.
| Autor: | Bhat V; Dr. Bhat is a Pharmacist Resident, Dr. McIntyre is a Medication Use Quality Manager, and Dr. Meyers is a Transplant Pharmacist, all in the Department of Pharmaceutical Services at Virginia Mason Medical Center in Seattle, Wash., McIntyre M, Meyers T |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | P & T : a peer-reviewed journal for formulary management [P T] 2010 Dec; Vol. 35 (12), pp. 676-9. |
| Abstrakt: | Purpose: We evaluated the efficacy and safety of the current cytomegalovirus (CMV) prophylaxis regimen used at Virginia Mason Medical Center in Seattle. Methods: A single-center, retrospective analysis was conducted in a regional renal transplantation center at a tertiary teaching facility. Study Population: Seventy patients who underwent kidney and/or pancreas transplantation from October 2006 through December 2008 were observed for a period of six months after the procedure. Transplant recipients at risk for developing CMV disease received valganciclovir 450 mg daily. Results: Outcome measures were incidence of CMV disease and incidence of severe leukopenia during the six-month postoperative period. Of 70 patients, seven (10%) developed CMV disease and five (7.1%) developed severe leukopenia while taking valganciclovir. Based on donor (D) and recipient (R) CMV serostatus, the incidence of CMV disease and severe leukopenia incidence was highest in the D+/R- group. Severe leukopenia developed in one patient with CMV disease who had a D+/R-kidney transplant. No statistical calculations were performed. Conclusion: The current lower-dose valganciclovir regimen at our institution was found to be efficacious and safe, and it provided significant cost savings. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|